NasdaqGS:RPRXPharmaceuticals
Accelerated Royalty Deals and Dividend Hike Could Be A Game Changer For Royalty Pharma (RPRX)
Royalty Pharma plc recently reported first-quarter 2026 results showing revenue of US$631 million and net income of US$295 million, both higher than a year earlier, alongside continued share repurchases under its existing buyback program.
Beyond the headline numbers, the company highlighted double-digit growth in recurring royalty receipts, increased its dividend, and committed over US$1.25 billion to new royalty and R&D funding deals, underscoring its role as a large-scale financier of...